These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 21724429)

  • 1. Clinicopathologic analysis of the impact of CD23 expression in plasma cell myeloma with t(11;14)(q13;q32).
    Buonaccorsi JN; Kroft SH; Harrington AM; VanTuinen P; Olteanu H
    Ann Diagn Pathol; 2011 Dec; 15(6):385-8. PubMed ID: 21724429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.
    Hoyer JD; Hanson CA; Fonseca R; Greipp PR; Dewald GW; Kurtin PJ
    Am J Clin Pathol; 2000 Jun; 113(6):831-7. PubMed ID: 10874884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic Study and Analysis of Protein Expression in Plasma Cell Myeloma with t(11;14)(q13;q32): Absence of BCL6 and SOX11, and Infrequent Expression of CD20 and PAX5.
    Yokoi S; Sakai H; Uchida A; Uemura Y; Sato K; Tsuruoka Y; Nishio Y; Matsunawa M; Suzuki Y; Isobe Y; Kato M; Inoue Y; Hoshikawa M; Miura I
    J Clin Exp Hematop; 2015; 55(3):137-43. PubMed ID: 26763361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.
    Tinguely M; Jenni B; Reineke T; Korol D; Kofler A; Rousson V; Dommann-Scherrer C; Maurer R; Moch H; Probst-Hensch NM
    Am J Surg Pathol; 2007 May; 31(5):690-6. PubMed ID: 17460451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD23 expression in follicular lymphoma: clinicopathologic correlations.
    Olteanu H; Fenske TS; Harrington AM; Szabo A; He P; Kroft SH
    Am J Clin Pathol; 2011 Jan; 135(1):46-53. PubMed ID: 21173123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.
    Sasaki K; Lu G; Saliba RM; Bashir Q; Hosing C; Popat U; Shah N; Parmar S; Dinh Y; Ahmed S; Shpall EJ; Kebriaei P; Shah JJ; Orlowski RZ; Champlin R; Qazilbash MH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1227-32. PubMed ID: 23733001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome.
    An G; Xu Y; Shi L; Zou D; Deng S; Sui W; Xie Z; Hao M; Chang H; Qiu L
    Leuk Res; 2013 Oct; 37(10):1251-7. PubMed ID: 23927993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome.
    Ngo NT; Brodie C; Giles C; Horncastle D; Klammer M; Lampert IA; Rahemtulla A; Naresh KN
    J Clin Pathol; 2009 Nov; 62(11):1009-15. PubMed ID: 19861559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation.
    Chang H; Qi X; Trieu Y; Xu W; Reader JC; Ning Y; Reece D
    Br J Haematol; 2006 Nov; 135(4):486-91. PubMed ID: 16995883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma.
    Olteanu H; Harrington AM; Kroft SH
    Am J Clin Pathol; 2012 Dec; 138(6):867-76. PubMed ID: 23161721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetics of multiple myeloma.
    Trcić RL; Skelin IK; Sustercić D; Planinc-Peraica A; Ajduković R; Haris V; Kusec R; Begović D
    Coll Antropol; 2010 Mar; 34(1):41-4. PubMed ID: 20432732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.
    Cook JR; Hsi ED; Worley S; Tubbs RR; Hussein M
    Am J Clin Pathol; 2006 Apr; 125(4):615-24. PubMed ID: 16627271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes.
    Mohamed AN; Bentley G; Bonnett ML; Zonder J; Al-Katib A
    Am J Hematol; 2007 Dec; 82(12):1080-7. PubMed ID: 17654686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).
    Pruneri G; Fabris S; Baldini L; Carboni N; Zagano S; Colombi MA; Ciceri G; Lombardi L; Rocchi M; Buffa R; Maiolo AT; Neri A
    Am J Pathol; 2000 May; 156(5):1505-13. PubMed ID: 10793062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
    Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
    Fonseca R; Blood EA; Oken MM; Kyle RA; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Hoyer JD; Harrington D; Kay NE; Van Ness B; Greipp PR
    Blood; 2002 May; 99(10):3735-41. PubMed ID: 11986230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.